A Review on Validated RP-HPLC Method for the Simultaneous Estimation of Serdexmethylphenidate and Dexmethylphenidate in Bulk and Pharmaceutical Dosage Form

An ADHD medication called Azstarys was approved by the FDA in March 2021.Because it combined serdexmethylphenidate and dexmethylphenidate for the first time, it is unique. Treatment for Attention Deficit Hyperactivity Disorder (ADHD) begins with a prodrug called serdexmethylphenidate. CNS stimulants include serdexmethylphenidate. People six years of age and older with attention deficit hyperactivity disorder (ADHD) are taken serdexmethylphenidate, a prodrug of dexmethylphenidate, in addition to dexmethylphenidate. Serdexmethylphenidate is a prodrug of the central nervous system stimulant dexmethylphenidate. It alters neurotransmission in the central nervous system by increasing extracellular dopamine and norepinephrine numbers.3[11] As a central nervous system stimulant, serdexmethylphenidate carries a risk of usage, addiction, and abuse that should be monitored. In addition, patients need to be assessed. The accuracy, precision, linearity, robustness, limits of detection and quantitation, system adaptability, robustness, and other factors can all be used to validate the RP-HPLC technology.